Viking Therapeutics Surges to 383rd in Trading Volume with 2.26 Billion Shares Exchanged

On April 14, 2025, Viking Therapeutics (VKTX) saw a significant surge in trading volume, reaching 2.26 billion, a 248.05% increase from the previous day. This placed VKTX at the 383rd position in terms of trading volume for the day. The stock has been on an upward trajectory, rising 10.58% on the day and 14.17% over the past two days.

Viking Therapeutics has recently announced that it has received a $10 million grant from the National Institutes of Health (NIH) to support its research and development efforts in the field of rare diseases. This grant is expected to accelerate the company's progress in developing new treatments for conditions that currently lack effective therapies.

In addition to the NIH grant, Viking Therapeutics has also been actively engaging with regulatory authorities to advance its pipeline of drug candidates. The company has submitted several Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA), seeking approval to initiate clinical trials for its most promising compounds.

Viking Therapeutics' recent developments have garnered attention from investors, who are optimistic about the company's potential to deliver innovative therapies to patients in need. The company's strong financial backing and strategic partnerships are expected to drive its growth in the coming years.